Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9585705 | 0.90 | CYP1A2 (0.39) | TSHRCA9CYP1A2CYP2D6MAPT | |
| SCHEMBL19233495 | 0.88 | MAPT (0.37) | TSHRCA9CYP1A2CYP2D6MAPT | |
| SCHEMBL25755556 | 0.87 | TSHR (0.37) | TSHRCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL25755554 | 0.87 | TSHR (0.48) | TSHRMAPTMAOAMAOB | |
| SCHEMBL22758907 | 0.87 | ODC1 (0.38) | TSHRCA9CA2 | |
| SCHEMBL1014592 | 0.87 | — | — | |
| SCHEMBL13913112 | 0.87 | — | — | |
| SCHEMBL15775433 | 0.87 | — | — | |
| SCHEMBL25032633 | 0.84 | — | — | |
| SCHEMBL22796821 | 0.84 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0760811-B1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 MODULATORS | INST NAT SANTE RECH MED (FR) | 2009-11-18 | — | — | EP | claimed |
| EP-0263259-B1 | PROCESS AND CATALYST SYSTEM FOR THE TRIMERIZATION OF ACETYLENE AND ACETYLENE COMPOUNDS | HÜLS AKTIENGESELLSCHAFT (DE) | 1991-06-19 | — | — | EP | claimed |
| WO-2015153217-A1 | CELLULOSE ETHERS HAVING 1,2,3-TRIAZOLYL SUBSTITUENTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153216-A1 | PENTYNYL CELLULOSE ETHERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140073658-A1 | Dipyridylamine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| EP-2684878-A1 | DIPYRIDYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-5248693-A | Antiallergens, antiinflammatory agents | CIBA-GEIGY CORPORATION (US) | 1993-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073658-A1 | Dipyridylamine Derivative | GCK, GCKR, GALK1 | TSHR 2035/4885CA9 3044/4885CYP1A2 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.